Skip to search formSkip to main contentSkip to account menu

cabergoline

Known as: cabergoline parkinsons, Cabergolina, (8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide 
A synthetic ergoline derivative and a long-acting dopamine receptor agonist with high affinity for the dopamine D2 receptor. Cabergoline exerts an… 
National Institutes of Health

Related topics

Related topics

11 relations

Broader (3)

Antineoplastic AgentsAntiparkinson AgentsDopamine Agonists
ErgolinesErgot AlkaloidsHyperprolactinemiaHypersensitivity

Narrower (2)

FCE 21336Galastop

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
A peek into the drug development scenario of endometriosis - A systematic review.
Review
2017
Review
2017
Therapeutics for Equine Endocrine Disorders.
Review
2011
Review
2011
The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists
Several observational studies suggest an association between treatment with ergoline‐derived dopamine agonists and valvular… 
2009
2009
Rapid left ventricular recovery after cabergoline treatment in a patient with peripartum cardiomyopathy
The aetiology of peripartum cardiomyopathy (PPCM) is still largely unknown. Recent evidence suggests that the breakdown products… 
2009
2009
Invasive Giant Prolactinoma with Loss of Therapeutic Response to Cabergoline: Expression of Angiogenic Markers
The present study reports the case of a 70-year-old Caucasian man who was referred to the Military Hospital of Buenos Aires for… 
Highly Cited
2005
Highly Cited
2005
Agonism at 5-HT2B receptors is not a class effect of the ergolines.
Review
2005
Review
2005
Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson’s disease patients treated with cabergoline
Summary.Background: Cardiac valvulopathy has been recently associated with the use of the ergot dopamine agonist (EDA) pergolide… 
Review
2004
Review
2004
Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms.
2003
2003
Cabergoline is an effective single-drug treatment for restless legs syndrome: clinical and actigraphic evaluation.
STUDY OBJECTIVES To evaluate the efficacy and the safety of cabergoline, a dopamine-receptor agonist with a long half-life, in… 
1993
1993
Controlled study of the antiparkinsonian activity and tolerability of cabergoline
Cabergoline, a new ergoline derivative, is a D2-specific dopaminergic agonist that is more potent and longer-acting than other… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)